These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 33616813)

  • 1. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.
    de Prost N; Bastard P; Arrestier R; Fourati S; Mahévas M; Burrel S; Dorgham K; Gorochov G; Tandjaoui-Lambiotte Y; Azzaoui I; Fernandes I; Combes A; Casanova JL; Mekontso-Dessap A; Luyt CE
    J Clin Immunol; 2021 Apr; 41(3):536-544. PubMed ID: 33616813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
    Solanich X; Rigo-Bonnin R; Gumucio VD; Bastard P; Rosain J; Philippot Q; Perez-Fernandez XL; Fuset-Cabanes MP; Gordillo-Benitez MÁ; Suarez-Cuartin G; Boza-Hernandez E; Riera-Mestre A; Parra-Martínez A; Colobran R; Antolí A; Navarro S; Rocamora-Blanch G; Framil M; Calatayud L; Corbella X; Casanova JL; Morandeira F; Sabater-Riera J
    J Clin Immunol; 2021 Nov; 41(8):1733-1744. PubMed ID: 34570326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.
    Troya J; Bastard P; Planas-Serra L; Ryan P; Ruiz M; de Carranza M; Torres J; Martínez A; Abel L; Casanova JL; Pujol A
    J Clin Immunol; 2021 Jul; 41(5):914-922. PubMed ID: 33851338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia.
    Philippot Q; Fekkar A; Gervais A; Le Voyer T; Boers LS; Conil C; Bizien L; de Brabander J; Duitman JW; Romano A; Rosain J; Blaize M; Migaud M; Jeljeli M; Hammadi B; Desmons A; Marchal A; ; ; Mayaux J; Zhang Q; Jouanguy E; Borie R; Crestani B; Luyt CE; Adle-Biassette H; Sene D; Megarbane B; Cobat A; Bastard P; Bos LDJ; Casanova JL; Puel A
    J Clin Immunol; 2023 Aug; 43(6):1093-1103. PubMed ID: 37209324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microarray-Based Detection of Antibodies against SARS-CoV-2 Proteins, Common Respiratory Viruses and Type I Interferons.
    Savvateeva E; Filippova M; Valuev-Elliston V; Nuralieva N; Yukina M; Troshina E; Baklaushev V; Ivanov A; Gryadunov D
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease.
    Busnadiego I; Abela IA; Frey PM; Hofmaenner DA; Scheier TC; Schuepbach RA; Buehler PK; Brugger SD; Hale BG
    PLoS Biol; 2022 Jul; 20(7):e3001709. PubMed ID: 35788562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 mRNA vaccine, but not a viral vector-based vaccine, promotes neutralizing anti-type I interferon autoantibody production in a small group of healthy individuals.
    Xu W; Wen X; Cong X; Jiang W
    J Med Virol; 2023 Oct; 95(10):e29137. PubMed ID: 37792386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.
    Bastard P; Orlova E; Sozaeva L; Lévy R; James A; Schmitt MM; Ochoa S; Kareva M; Rodina Y; Gervais A; Le Voyer T; Rosain J; Philippot Q; Neehus AL; Shaw E; Migaud M; Bizien L; Ekwall O; Berg S; Beccuti G; Ghizzoni L; Thiriez G; Pavot A; Goujard C; Frémond ML; Carter E; Rothenbuhler A; Linglart A; Mignot B; Comte A; Cheikh N; Hermine O; Breivik L; Husebye ES; Humbert S; Rohrlich P; Coaquette A; Vuoto F; Faure K; Mahlaoui N; Kotnik P; Battelino T; Trebušak Podkrajšek K; Kisand K; Ferré EMN; DiMaggio T; Rosen LB; Burbelo PD; McIntyre M; Kann NY; Shcherbina A; Pavlova M; Kolodkina A; Holland SM; Zhang SY; Crow YJ; Notarangelo LD; Su HC; Abel L; Anderson MS; Jouanguy E; Neven B; Puel A; Casanova JL; Lionakis MS
    J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33890986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
    Bastard P; Rosen LB; Zhang Q; Michailidis E; Hoffmann HH; Zhang Y; Dorgham K; Philippot Q; Rosain J; Béziat V; Manry J; Shaw E; Haljasmägi L; Peterson P; Lorenzo L; Bizien L; Trouillet-Assant S; Dobbs K; de Jesus AA; Belot A; Kallaste A; Catherinot E; Tandjaoui-Lambiotte Y; Le Pen J; Kerner G; Bigio B; Seeleuthner Y; Yang R; Bolze A; Spaan AN; Delmonte OM; Abers MS; Aiuti A; Casari G; Lampasona V; Piemonti L; Ciceri F; Bilguvar K; Lifton RP; Vasse M; Smadja DM; Migaud M; Hadjadj J; Terrier B; Duffy D; Quintana-Murci L; van de Beek D; Roussel L; Vinh DC; Tangye SG; Haerynck F; Dalmau D; Martinez-Picado J; Brodin P; Nussenzweig MC; Boisson-Dupuis S; Rodríguez-Gallego C; Vogt G; Mogensen TH; Oler AJ; Gu J; Burbelo PD; Cohen JI; Biondi A; Bettini LR; D'Angio M; Bonfanti P; Rossignol P; Mayaux J; Rieux-Laucat F; Husebye ES; Fusco F; Ursini MV; Imberti L; Sottini A; Paghera S; Quiros-Roldan E; Rossi C; Castagnoli R; Montagna D; Licari A; Marseglia GL; Duval X; Ghosn J; ; ; ; ; ; ; ; ; ; ; Tsang JS; Goldbach-Mansky R; Kisand K; Lionakis MS; Puel A; Zhang SY; Holland SM; Gorochov G; Jouanguy E; Rice CM; Cobat A; Notarangelo LD; Abel L; Su HC; Casanova JL
    Science; 2020 Oct; 370(6515):. PubMed ID: 32972996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.
    Lopez J; Mommert M; Mouton W; Pizzorno A; Brengel-Pesce K; Mezidi M; Villard M; Lina B; Richard JC; Fassier JB; Cheynet V; Padey B; Duliere V; Julien T; Paul S; Bastard P; Belot A; Bal A; Casanova JL; Rosa-Calatrava M; Morfin F; Walzer T; Trouillet-Assant S
    J Exp Med; 2021 Oct; 218(10):. PubMed ID: 34357402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1.
    Meisel C; Akbil B; Meyer T; Lankes E; Corman VM; Staudacher O; Unterwalder N; Kölsch U; Drosten C; Mall MA; Kallinich T; Schnabel D; Goffinet C; von Bernuth H
    J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary autoantibodies to type I IFNs: Mirror plasma levels, predispose to severe COVID-19, and enhance feasibility for clinical screening.
    Saheb Sharif-Askari N; Saheb Sharif-Askari F; Bayram OS; Hafezi S; Alsayed HAH; Kasim F; Mdkhana B; Selvakumar B; Alsafar HS; Halwani R
    Heart Lung; 2024; 66():31-36. PubMed ID: 38547583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.
    Chauvineau-Grenier A; Bastard P; Servajean A; Gervais A; Rosain J; Jouanguy E; Cobat A; Casanova JL; Rossi B
    J Clin Immunol; 2022 Apr; 42(3):459-470. PubMed ID: 35083626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol.
    Faqihi F; Alharthy A; Alodat M; Asad D; Aletreby W; Kutsogiannis DJ; Brindley PG; Karakitsos D
    Trials; 2020 Jun; 21(1):506. PubMed ID: 32513290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I interferons and SARS-CoV-2: from cells to organisms.
    Bastard P; Zhang Q; Zhang SY; Jouanguy E; Casanova JL
    Curr Opin Immunol; 2022 Feb; 74():172-182. PubMed ID: 35149239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia.
    Bastard P; Zhang Q; Cobat A; Jouanguy E; Zhang SY; Abel L; Casanova JL
    C R Biol; 2021 Jun; 344(1):19-25. PubMed ID: 34213846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies.
    Akbil B; Meyer T; Stubbemann P; Thibeault C; Staudacher O; Niemeyer D; Jansen J; Mühlemann B; Doehn J; Tabeling C; Nusshag C; Hirzel C; Sanchez DS; Nieters A; Lother A; Duerschmied D; Schallner N; Lieberum JN; August D; Rieg S; Falcone V; Hengel H; Kölsch U; Unterwalder N; Hübner RH; Jones TC; Suttorp N; Drosten C; Warnatz K; Spinetti T; Schefold JC; Dörner T; Sander LE; Corman VM; Merle U; ; Kurth F; von Bernuth H; Meisel C; Goffinet C
    J Clin Immunol; 2022 Aug; 42(6):1111-1129. PubMed ID: 35511314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.
    Wang X; Tang Q; Li H; Jiang H; Xu J; Bergquist R; Qin Z
    Int J Infect Dis; 2023 May; 130():147-152. PubMed ID: 36907547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.
    Mathian A; Breillat P; Dorgham K; Bastard P; Charre C; Lhote R; Quentric P; Moyon Q; Mariaggi AA; Mouries-Martin S; Mellot C; Anna F; Haroche J; Cohen-Aubart F; Sterlin D; Zahr N; Gervais A; Le Voyer T; Bizien L; Amiot Q; Pha M; Hié M; Chasset F; Yssel H; Miyara M; Charneau P; Ghillani-Dalbin P; Casanova JL; Rozenberg F; Amoura Z; Gorochov G
    Ann Rheum Dis; 2022 Dec; 81(12):1695-1703. PubMed ID: 35973806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients.
    Aoki A; Iwamura C; Kiuchi M; Tsuji K; Sasaki A; Hishiya T; Hirasawa R; Kokubo K; Kuriyama S; Onodera A; Shimada T; Nagaoka T; Ishikawa S; Kojima A; Mito H; Hase R; Kasahara Y; Kuriyama N; Nakamura S; Urushibara T; Kaneda S; Sakao S; Nishida O; Takahashi K; Kimura MY; Motohashi S; Igari H; Ikehara Y; Nakajima H; Suzuki T; Hanaoka H; Nakada TA; Kikuchi T; Nakayama T; Yokote K; Hirahara K
    J Clin Immunol; 2024 Apr; 44(4):104. PubMed ID: 38647550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.